The triumphant rise of India's pharmaceutical industry is characterised with consistent growth and being a leader in supplier of affordable drugs over the last three decades. As a result, the Indian pharmaceutical industry today stands as the third-largest globally in terms of volume. It is expected to become the world's largest supplier of drugs by volume as well as one of the top five pharmaceutical markets globally by 2030. India is also the 3rd largest manufacturer of active pharmaceutical ingredient (API) in the Asia-Pacific region


One of the key segments in the Indian pharma industry is the biopharmaceutical industry, which contributes approximately US$4 billion. When it comes to Bio-pharmaceutical manufacturing companies in India, Concord Biotech Limited is a leading name. Concord is a vertically integrated, R&D driven biotechnological powerhouse that manufactures Active Pharmaceutical Ingredients, through fermentation and semi-synthetic process, and finished formulations. Founded in the year 2000, Concord Biotech has completely transformed from a single-product company to a broad-spectrum specialty drug provider, offering products across diversified therapeutic segments, including niche and complex therapies such as Immunosuppressant, Antibiotics, novel Antifungal and Oncology.

Concord offers a world-class API production infrastructure at Dholka, located near Ahmedabad, Gujarat, India which is spread across 114,000 sq. meters. It is a hub to the largest number of bioreactors in India with a fermentation capacity of more than 500 m3 and is in the process of constructing a new facility that will catapult Concord as the largest manufacturer of fermentation based small molecules. The manufacturing facility complies with cGMP and has been inspected by global regulatory agencies like U.S. Food & Drug Administration (USFDA), European Union Goods Manufacturing Practice (EUGMP), Japanese Accreditation of Foreign Manufacturers (AFM), and Korean Food & Drug Administration & State Goods Manufacturing Practice of India (GMP). Concord has commercialized APIs across high growth, specialty therapeutic segments like Immunosuppressant, Hematology, Oncology, Anti-fungal, Antibacterial and Anthelmintic (Animal health). Fermentation-based products had been a challenge to India and India was totally dependent on China but Concord became the first company to take this challenge and is now exporting the fermentation based products to various countries across the globe including China.

Concord also offers Contract Research & Manufacturing services of APIs in the area of fermentation & semi-synthetic molecules.  All in all, Concord is focused on becoming a strong player in Contract Research and Manufacturing of fermentation and semi-synthesis based Bio-pharmaceuticals through its expertise in…

  • Strain Improvement & Media Optimization
  • Fermentation/ Biotransformation process development
  • Down Stream & Semi-Synthetic/ Synthetic process development
  • Process scale-up & Optimization

In 2016, Concord forward integrated to finished formulations with a vision to supply globally including the regulated markets, focusing initially on solid orals, liquid orals & topical of Immunosuppressant products and then followed by a solid oral dosage of Oncology and specialty formulations.


Sudhir Vaid

Sudhir Vaid is the man behind the victorious journey of Concord Biotech. He is the Chairman and Managing Director of the company and holds over 40 years of extensive experience in the field of corporate R&D & consultancy with leading domestic & global API companies.

 Researcher turned entrepreneur, Sudhir has interest in Pharmaceutical Industries (Generic & Branded), Biotechnology, and Life Sciences (including Medical Devices). Since 2000, he has been instrumental in building Concord Biotech, from a start-up venture into one of India's leading manufacturers of active pharmaceutical ingredients and formulations.

Ankur Vaid

Ankur Vaid is a big influence in developing the R&D division, contributing to the market strategy and at the same time, spearheading the entire organisation towards its goals and objectives. Ankur did his masters in Finance after completing his graduation in Chemical Engineering. Playing a vital role in the promoter group, he has performed tremendously across various business verticals and brought efficiencies thus providing a major boost to the growth of the company.


The founder of Concord Biotech, Sudhir Vaid considers Gujarat as his "Karma Bhumi", and took over the multinational manufacturing unit in Dholka in 2000. Later, he transformed this chemical facility to Biotech facility by starting production of its first product Amidase Immobilized Enzyme. With his core strength in fermentation, Concord then diversified itself into fermentation-based niche API manufacturing from 2003.

Today, Concord has become one of the largest manufacturers of fermentation-based APIs in the world with more than 20 dedicated API manufacturing blocks having over 500 M3 fermentation capacities. As a part of the forward integration strategy, Concord has now ventured into Finished Dosage Form. A state-of-the-art formulation, development and manufacturing facility spread over 95000 Sq. meters at Valthera, located near Ahmedabad, India was commissioned in 2016 to manufacture pharmaceutical dosage forms like solid orals, oral liquid, and suspensions, complying with global regulatory norms and already accredited by the US-FDA The company has also initiated selling of finished dosage products in the USA.


The team of Concord Biotech combines expert professionals specializing in the field of pharmaceuticals. The team is a perfect blend of highly competent Biotechnologists, Biochemists, Chemists, and Engineers, Pharmacists and Management experts, who are continuously focusing on the development of high-value & low-volume Biotech APIs and complex Finished Dosage Forms.

Concord Biotech is globally recognized for its products and has a commanding presence in more than 50 countries worldwide and supplying to some of the leading MNC and Indian Pharma companies across North America, Europe, Japan, Central & Latin America, Africa, Australia, New Zealand, Asia-Pacific as well as CIS and MENA countries, besides significant presence in India.

 With respect to finished formulation, at present Concord Biotech is serving 1200+ Nephrologists, 250+ Transplant Physicians & 250+Immunologists/ Rheumatologists & 500+ Intensivists based at major Tertiary healthcare centres. Concord is  linked with more than 500+ Healthcare Centres with its  available product range and distribution network which involves 120+ Supply Chain Management Partners. The in-house products of the company are available in major Corporate Hospitals & Government Setups.

Here Road ahead:


Concord is an R&D based Biotechnology company having state-of-the-art Fermentation Facility. Here is the list of major driving force that makes this company stand out in the market:

  • Concord offers a fully integrated platform with a diversified portfolio of Active Pharmaceutical Ingredients and finished dosage products in the area of Statins, Immunosuppressant, Antibiotics, Anti-fungal, Oncology, Anti-Obesity, and others.
  • Concord has a strong track record of product development capabilities, with expertise in developing complex molecules with non-infringing processes
  • Concord has a quality driven approach with a regulatory market mindset and has been inspected by numerous global regulatory agencies like US-FDA, EU-GMP, Japanese AFM and local FDA.
  • It has the largest number of Bioreactors in India with total fermentation capacity>500m3 and additional capacity of >1200m3 which will be ready in the second quarter of 2020.
  • Concord's 20 Dedicated API manufacturing blocks for the different class of products allows the company high flexibility in manufacturing at competitive cost
  • There is a competent and proficient team of scientists to handle various projects in defined targets/ timelines.
  • Having a presence in the global market and working with key global pharmaceutical and biotech giants in the world


Concord Biotech is creating strategies to expand its manufacturing capacities to support the increasing demand for its commercial and pipeline products. It has acquired 160 Acres of land in Gujarat and started the implementation of the state of the art world's largest Biotechnology facility with respect to number of bioreactors. The facility will be ready in May – June 2020.   Concord is also on the way to expand its horizons by partnering with leading Global Pharmaceutical Companies by meeting their product development needs for API's & Finished Formulations.

Get The CEO Magazine to your Door Steps; Subscribe Now

Software Suggestion

No stories found.

Best Place to Work

No stories found.

CEO Profiles

No stories found.

Best Consultants

No stories found.

Tips Start Your Own Business

No stories found.